In the US, Tafinlar (dabrafenib systemic) is a member of the drug class multikinase inhibitors and is used to treat Melanoma, Metastatic.
Ingredient matches for Tafinlar
Dabrafenib is reported as an ingredient of Tafinlar in the following countries:
- Bosnia & Herzegowina
- Croatia (Hrvatska)
Dabrafenib mesylate (a derivative of Dabrafenib) is reported as an ingredient of Tafinlar in the following countries:
- United Kingdom
- United States
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.